MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds

thought leadership

Making the complexity of cell and gene science simple for your stakeholders

Catriona Marshall, Manager, Medical Communications & Business Development, and Amy Jackson, Executive Director, Medical Writing | 9/25/2023

Learn from our medical communication experts the steps you need to take to ensure your audience understands the high science you want to communicate.

Mutations in the gene encoding adenosine deaminase (ADA; a key enzyme of the purine salvage pathways) cause the autosomal recessive disease severe combined immunodeficiency (SCID). When ADA function is absent or impaired, the toxic metabolites adenosine, 2’-deoxyadenosine, and deoxyadenosine triphosphate accumulate in cells, causing severe lymphocytopenia affecting T‑ and B‑lymphocytes and NK cells.

Hang on, you’ve lost me. What does that ACTUALLY mean? And how useful was that little piece of text? It all depends on your level of scientific and medical knowledge of your audience.

For the general public

This paragraph would be simply dismissed— it’s impenetrable. For the more scientifically and medically literate, it may translate into “a mutation causes SCID, which sounds like bad news, a bit like AIDS.”

For a non-expert healthcare professional (HCP)

The key piece of information about lymphocytopenia may provide a bit of extra context about how the disease could impact patients, with the gravity of the condition extrapolated from the name (severe! [and] combined! immunodeficiency disease).

For the expert

The paragraph is probably redundant. You aren’t telling them anything they do not already know, and you’re possibly taking up valuable time.

Clearly, communicating your message in the right way for your target audience is key, and although we all have access to vast amounts of information at our fingertips, the job is not straightforward. This is especially true for complex and targeted cell and gene therapies with novel modes of action that leverage novel biomarkers and complex delivery methods.

The science behind these therapies is at the cutting edge of healthcare innovation, and there is a wide range of understanding (from none to highly literate) across both patient and healthcare professional populations that must be considered when planning a communication.

For patients, regulators, payers, and healthcare professionals alike, questions are also raised about the robust nature of the data—especially for accelerated approvals. As a result, conversations around the risk and benefit of these therapies become more challenging: Digestible communications are needed to help those who are not experts in the science make (the right) decisions.

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement


Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.